Drug Profile


Alternative Names: D-chiro-inositol

Latest Information Update: 08 Jan 2003

Price : $50

At a glance

  • Originator Insmed
  • Developer Insmed; Taisho Pharmaceutical
  • Class Cyclohexanes; Small molecules; Sugar alcohols
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperlipidaemia; Polycystic ovary syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 23 Sep 2002 Discontinued - Phase-II for Hyperlipidaemia in USA (PO)
  • 23 Sep 2002 Discontinued - Phase-I for Type-2 diabetes mellitus in United Kingdom (PO)
  • 23 Sep 2002 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top